Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | BCL6 | P41182 | 3/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836897 | 0.87 | MAPT (0.74) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4836233 | 0.86 | MAPT (0.60) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4838460 | 0.85 | MAPT (0.72) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4873970 | 0.84 | MAPT (0.58) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4829511 | 0.82 | MAPT (0.75) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4832464 | 0.82 | MAPT (0.75) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4832619 | 0.80 | MAPT (0.64) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL4873964 | 0.79 | MAPT (0.57) | MAPTMEN1LMNAKMT2AGAA | |
| SCHEMBL1391478 | 0.79 | PDE4B (0.81) | MAPTMEN1LMNAKMT2ARECQL | |
| SCHEMBL19053363 | 0.78 | MAPT (1.00) | MAPTMEN1LMNAKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | MAPT 3539/4885MEN1 4761/4885LMNA 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.